Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20679525 | 1.00 | KCNH2 (0.55) | KCNH2SLC2A1AVPR1BADORA2A | |
| SCHEMBL4305547 | 0.95 | KCNH2 (0.52) | KCNH2AVPR1B | |
| SCHEMBL4303013 | 0.90 | KCNH2 (0.48) | KCNH2SLC2A1AVPR1B | |
| SCHEMBL18544235 | 0.89 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL4298780 | 0.89 | KCNH2 (0.55) | KCNH2 | |
| SCHEMBL18544260 | 0.86 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL18544255 | 0.85 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL18544187 | 0.85 | KCNH2 (0.56) | KCNH2ADORA2A | |
| SCHEMBL18544186 | 0.85 | KCNH2 (0.56) | KCNH2ADORA2A | |
| SCHEMBL4303090 | 0.85 | KCNH2 (0.52) | KCNH2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683307-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| US-20190270755-A1 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10364254-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| EP-3334739-A2 | ANTIBACTERIAL AGENTS COMPRISING A PYRAZINO[2,3-B][1,4]OXAZIN-3-ONE OR A RELATED RING SYSTEM | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017029602-A2 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683307-B2 | Compounds for use in antibacterial applications | MRPL21, CFTR, NRDC | KCNH2 2823/4885SLC2A1 2521/4885AVPR1B 3366/4885 |
| US-20190270755-A1 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | MRPL21, CFTR, NRDC | KCNH2 2823/4885SLC2A1 2521/4885AVPR1B 3366/4885 |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | CFTR, MRPL21, CLPP | KCNH2 2998/4885SLC2A1 3134/4885AVPR1B 4110/4885 |
| US-10364254-B2 | Compounds for use in antibacterial applications | MRPL21, CFTR, NRDC | KCNH2 2823/4885SLC2A1 2521/4885AVPR1B 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.